Leishmaniasis

Tropical Dermatology

Volumn , Issue , 2006, Pages 41-48

  Machado Pinto, Jackson ^a   Azulay, Rubem David ^b  

^a Hospital Belo Horizonte   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38649091470     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06790-7.50009-0     Document Type: Chapter

References (39)

1. Desjeux P Information on the epidemiology and control of leishmaniasis by country and territory. WHO/Leish 1991, 91:47.
2. Centers for Disease Control and Prevention Identification and diagnosis of parasites of public health concern (updated February, 2001; accessed November 11,2003). http://www.cdc.gov.
3. Alexander J Unusual axonemal doublet arrangements in the flagellum of Leishmania amastigotes. Trans R Soc Trop Méd Hyg 1978, 72:345-347.
4. Furtado TA Leishmaniose tegumentar americana. Doenças infecciosas com manifestações dermatológicas 1994, 319-328. Editora Medsi, Rio de Janeiro. J. Machado-Pinto (Ed.).
5. Wirth DF, Rogers WO, Barker R, et al. Leishmaniasis and malaria: new tools for epidemiologic analysis. Science 1986, 234:975-979.
6. World Health Organization.Division of Control of Tropical Diseases Leishmaniasis control (updated December, 2000), accessed November 11, 2003. http://www.who.int/health-topics/leishmaniasis.htm.
7. Lainson R Ecological interactions in the transmission of the leishmaniases. Phil Trans R Soc 1988, 321:389-404.
8. Coutinho SG, Louis JA, Mavel J, et al. Induction of specific T lymphocytes of intracellular destruction of Leishmania major in infected murine macrophages. Parasit Immunol 1984, 6:157-169.
9. Pirmez C, Cooper C, Paes-Oliveira M, et al. Immunologic responsiveness in American cutaneous leishmaniasis lesions. J Immunol 1990, 145:3100-3104.
10. Mossmann TR, Coffman RL Two types of mouse helper T-cell clones: implications for immune regulation. Immunol Today 1987, 8:223-227.
11. Fiorentino DF, Bond DW, Mossmann TR Two types of mouse T-helper cell IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095.
12. Scott P Host and parasite factors regulating the development of CD4+ subjects in experimental cutaneous leishmaniasis. Res Immunol 1991, 142:32-35.
13. Pirmez C, Yamamura M, Uyemura K, et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993, 91:1390-1395.
14. Reiner SL, Zheng S, Corry DB, et al. Constructing poly-competitor cDNAs for quantitative PCR. J Immunol Meth 1994, 175:275.
15. DaCruz AM, de Oliveira MP, de Luca PM, et al. Tumor necrosis factor-alpha in human American tegumentary leishmaniasis. Mem Inst O Cruz 1996, 91:225-229.
16. Trinchieri G Role of interleukin-12 in human Th1 response. Chem Immunol 1996, 63:14-29.
17. Carvalho EM, Correia-Filho D, Bacellar O, et al. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 1995, 53:273-277.
18. Bacellar O, Lessa H, Schriefer A, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002, 70:6734-6740.
19. Bonfim G, Nascimento C, Costa J, et al. Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol 1996, 84:188-194.
20. d'Oliveira A, Costa SR, Barbosa AB, et al. Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst O Cruz 1997, 95:15-20.
21. Marzochi MCA Leishmanioses no Brasil. As leishmanioses tegumentares. J Brãs Méd 1992, 63:82-95.
22. Mayrink W, Costa CA, Magalhães PA A field trial of a vaccine against American leishmaniasis. Trans R Soc Trop Med Hyg 1979, 73:385-387.
23. Passos VMA, Barreto SM, Romanha AJ, et al. American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull WHO 2000, 78:968-974.
24. Rodriguez V, Centeno M, Ulrich M The IgG isotypes of specific antibodies in patients with American cutaneous leishmaniasis: relationship to the T-cell mediated immune response. Parasit Immunol 1996, 18:341-345.
25. Pessoa SB Profilaxia da leishmaniose tegumentar no estado de São Paulo. Folha Méd 1941, 22:157-161.
26. Diógenes MJN, Alencar JE, Menezes RHO, et al. Leishmaniose visceral americana. Doenças infecciosas com manifestações dermatológicas 1994, 328-338. Editora Medsi, Rio de Janeiro. J. Machado-Pinto (Ed.).
27. Machado-Pinto J, Pinto J, Costa CA, et al. Immunochemo-therapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 2002, 41:73-78.
28. Berman J Current treatment approaches in leishmaniasis. Curr Opin Infect Dis 2003, 16:397-401.
29. Asilian A, Jalayer T, Nilforooshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull WHO 2003, 81:353-359.
30. Magalhaes PA, Mayrink W, Costa CA, et al. Calazar na zona do Rio Doce-minas gerais. Resultados de medidas profilãticas. Rev Inst Med Trop São Paulo 1980, 22:197-202.
31. Arana BA, Navin TR, Arana FE, et al. Efficaccy of a short course (10 days) of high dose meglumine antimoniate with or without interferonamp-gamma; in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994, 18:381-384.
32. Kopke LFF, Café MEM, Neves LB, et al. Morte após uso de antimonial pentavalente em leishmaniose tegumentar americana. An Bras Dermatol 1993, 68:259-262.
33. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001, 65:87-89.
34. De Paula CD, Sampaio JH, Cardoso DR, et al. A comparative study between the efficaccy of pentamidine isothianate given in three doses for one week and N-methyl-glucamine in a dose of 20 mgsbv/day for 20 days to treat cutaneous leishmaniasis. Rev Soc Bras Med Trop 2003, 36:365-371.
35. Murdaca G, Setti M, Campelli A, et al. Liposomal amphotericin B for the treatment of acute phase and secondary prophylaxis of visceral leishmaniasis in a HIV positive patient. Infez Med 2000, 8:241-244.
36. Mayrink W, Pinto JA, Costa CA, et al. Evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis. Am J Trop Med Hyg 1999, 61:294-295.
37. Kenney RT, Sacks DL, Sypek JP, et al. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163:4481-4488.
38. Armijos RX, Weigel MM, Aviles H, et al. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety immunogenicity and eficaccy during the first 12 months of follow-up. J Infect Dis 1998, 177:1352-1357.
39. Sharifi I, Fekri AR, Aflatonian MR, et al. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351:1540-1543.